Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05515640
Other study ID # 2019-5610
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date August 1, 2019
Est. completion date June 2024

Study information

Verified date March 2024
Source Karolinska University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Following brain injury, complex interactions between the nervous system and other organs are frequently encountered. Systemic effects may be induced by dysregulation of the hypothalamic-pituitary-adrenal axis and the autonomic nervous system. This observational study will investigate the link between clinical, physiological and biochemical expressions of dysautonomic reactions and physiological stress, and their relations to sympathetic activation in traumatic brain injury patients treated in the neurointensive care unit.


Description:

Following traumatic brain injury (TBI) complex interactions between the nervous system and other organs are frequently encountered. Systemic reactions may be induced by dys-regulation of the hypothalamic-pituitary adrenal (HPA) axis and the autonomic nervous system. Neuro-endocrine disturbances are common and up to 50 % of brain injured Neuro-intensive care (NICU) patients may exhibit a period of relative adreno-cortico insufficiency in the early phase of TBI, which in part may be centrally mediated. Catecholamine surge is thought responsible for cardio pulmonary reactions such as myocardial stunning, and may be an instrumental part of neurogenic pulmonary edema. An imbalance between the parasympathetic and sympathetic nervous system has been identified, and may even effect outcome, but is poorly understood. This is seen both in early and chronic stages of brain injury. Heart rate variability has been implicated as an indicator of dys-autonomic parasympathetic dysfunction, and has in small studies been related to TBI outcome. Recently a clinical definition of Paroxysmal Sympathetic Hyper-activation (PSH) has been suggested and identities as related to patient outcome. Thus, in TBI the picture of a triad of dysautonomic and hypothalamic-pituitary dysregulation and injury driven inflammation, with a potential of bi-directional cross-talk between central and peripheral immuno- modulators, is emerging. This study will aim to explore and integrate indicators of these three components as to define phenotypes. It will investigate the utility of medically approved (CE) Skin Conductance Algesimeter (Med-Storm ®) in relation to other parameters of physiological stress including, heart rate variability (HRV), intra-cranial pressure reactivity index (PrX), and products of the HPA axis such as, ACTH, adrenaline and nor-adrenaline including break down products, markers of brain trauma driven neuro and systemic inflammation. The investigators hypothesize that a limited number of composite patterns will emerge and may describe patient phenotypes with differing trajectories. CRF: Electronic case report form (eCRF) with pseudo anonymized data via a globally unique personal identifier (GUPI) to secure eCRF platform. Patient Key kept locally and GDPR compliant. Variables: Baseline variables including IMPACT calculator variables for co-variate adjustment and trauma time, including predictors from the from Karolinska Traumatic Brain injury Database. Additional parameters of injury severity assessment and outcome predictors: Intracranial injury severity scoring on computed tomography (CT) scan by abbreviated injury severity score, Marshall CT classification, Rotterdam CT score, Helsinki CT score and Stockholm CT score. Severity scoring on magnetic resonance imaging (MRI) (if available) focusing on the presence of diffuse axonal injury (DAI), burden and region of DAI. Concomitant drugs of interest, such as analgesics, sedation, alpha II agonists, betablockers, vasopressor support. Daily injury severity scores. Daily symptom assessment of paroxysmal sympathetic hyperactivity (PSH) in relation to guideline definition. Daily Therapy Intensity level (TIL) and individual components. Daily Pain assessment scores. Available relevant clinical lab data in hospital system such as S100B, ProBNP, Troponins TSH,T3,T4. High resolution physiological data, physiological monitoring during ICU stay. Physiological monitoring via ICM+ including intracranial pressure (ICP), Brain tissue oxygenation (PbtO2), ECG waveform and heart rate variability (HRV), Central Temperature (Temp) , Saturation (SaO2). Pulse reactivity Index (PrX). Med-Storm Skin Conductance Algesimeter measure of sympathetic activity. ICM + ® annotation tool: Time-stamped changes in sedation and potentially painful and stressful clinical interventions. Bio-sampling: Biomaterial bio-banked for analyses Collection of plasma (from 4 ml whole blood sample) Daily, day 1-7, sampled from arterial line when available clinically. Cerebral Microdialysis: hourly when clinically available, pooled. Cerebral spinal fluid(CSF): Daily (2 ml), when clinically available from EVD catheter, day 1-7. Urine: Daily mixed aliquot (20 ml) of a 6 hour measured collection, day 1-7. Samples centrifuged 20G-15min: Aliquots of 200 μl and frozen with sample to freezer time recorded. Outcome Follow-up: Extended Glasgow Outcome Scale (GOSE) questionnaire and/or interview at 3, 6 and 12 months. Extraction from Karolinska Traumatic Brain injury Database. Death Date. Planned analyses: Wet-lab Proteomics: protein profiling of brain enriched and inflammatory proteins from serum, CSF and cerebral microdialysis. Microparticles/ exosomes, microRNA of central origin in CSF, microdialysate and plasma. HPA axis parameters and breakdown products including cortisol, catecholamines, metanephrines. Specific parameters of inflammatory crosstalk periphery/brain including choline acetyl transferase, HMGB1 as well as peripheral and central modulators of levels of T and B cell subgroup and glial activation. Analytics: Signal decomposition of physiological variables: ECG derived metrics including decreased baroreflex sensitivity (BRS), low frequency (LF), high frequency (HF) and total power (TP). Entropy. HRV. Signal analysis including FFT and wavelet. ICP derived metrics including PrX. Dimensionality reduction techniques such as principle component analysis (PCA) and non-supervised clustering techniques. Time series analyses: Cross-correlations and Trajectory analyses, Deep learning


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 24
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age 18 years or over. - Patients suffering from TBI, in need of neurocritical care and intracranial pressure measurement Exclusion Criteria: - Trauma more than 24 hours prior to inclusion. Goal for inclusion is less than 12 hours. - TBI unlikely to survive five days (as judged by clinical team, such as bilateral fixed and dilated pupils). - Follow up not possible

Study Design


Locations

Country Name City State
Sweden Perioperative Medicine and Intensive Care, Karolinska University Hospital Stockholm

Sponsors (4)

Lead Sponsor Collaborator
Karolinska University Hospital Eurostars, Region Stockholm, Vinnova

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Extended Glasgow Outcome Scale (EGOS) EGOS will be recorded at 4-6 months for demographic purposes, however sample size does not permit analysis related to this outcome 4-6 months
Primary Skin Conductance Algesimeter the Skin Conductance Algometer (MedStorm (R)) as conductance in microvolts and algesimeter index as peaks/second. up to one week
Primary Stress biomarkers Cortsol and adrengeric breakdown metabolites up to one week in ICU
Secondary Exploratory hypothesis-generating analysis of interactions/crosstalk between dysautonomia, the hypothalamic-pituitary-adrenal axis and neuroinflammation. As to elucidate if indices of systemic sympathetic activation in severe TBI can be used to monitor expression of paroxysmal sympathetic hyperactivity, multiple cross-correlations of time series data will explored to better understand temporal associations. Thus a specific outcome is not sought but strengths of temporal associations. This will also include dimensionality reduction reduce and identify a finite number of phenotypes with clustering techniques. Collected during ICU stay up to one week.
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1